🟢 OTLK is trading 5.7% up today on continued momentum from FDA appeal victory and BLA resubmission

OTLK is trading 5.7% up at $1.53 following a recent FDA appeal victory and the June 1 BLA resubmission for ONS-5010 (Lytenava).

• The FDA confirmed that substantial evidence of effectiveness was established for wet AMD, with the resubmission expected to be reviewed on a Class 1 timeline within approximately 60 days.
• The price action reflects continued investor interest in the regulatory catalyst alongside positive broader U.S. pre-market sentiment in the S&P 500 and Nasdaq futures.